Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin

International Journal of Cancer

Volumn 122, Issue 10, 2008, Pages 2380-2384

  Myoung, Woo Lee ^a   Dae, Seong Kim ^a   Na, Young Min ^a   Heung, Tae Kim ^a  

^a National Cancer Center   (South Korea)

Author keywords

Akt1; Cisplatin; Non small cell lung cancer; siRNA

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN AKT1; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; MAP2K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1;

APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; IMMUNOBLOTTING; LENTIVIRINAE; LUNG TUMOR; METABOLISM; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; IMMUNOBLOTTING; LENTIVIRUS; LUNG NEOPLASMS; MAP KINASE KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 42149159986     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23371     Document Type: Article

References (11)

1. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001;98:10983-5.
2. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
3. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65.
4. Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A. Matsuoka T, Jikihara H, Mercola D, Murata Y. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 1999;274:31648-54.
5. Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 2000;275:39435-43.
6. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003;22:9030-40.
7. Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 2005;65:8423-32.
8. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995;81:727-36.
9. Aoki M, Schetter C, Himly M, Batista O, Chang HW, Vogt PK. The catalytic subunit of phosphoinositide 3-kinase: requirements for oncogenicity. J Biol Chem 2000;275:6267-75.
10. Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res 2000;60:5390-4.
11. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999;286:1741-4.